论文部分内容阅读
目的多种含铂药物联合对晚期非小细胞肺癌(NSCLC)的治疗效果相似,确定不同联合方案对鳞癌和非鳞癌的相对效率和可比性。方法通过本院数据库确定一线化疗药物对2000~2007年NSCLCⅢB期或Ⅳ期患者的治疗效果进行研究。比较卡铂+紫杉醇、卡铂+吉西他滨和卡铂+多西他赛3种化疗方案的患者总存活率。结果接受一线化疗的1011例患者中,438例患者接受卡铂+紫杉醇治疗,281例患者接受卡铂+吉西他滨治疗,247例患者接受卡铂+多西他赛治疗,另外45例患者接受其他治疗方案。卡铂+紫杉醇组患者的生存中值为8.0个月[四分位距(IQR)为3.5~17.4个月],卡铂+吉西他滨组患者的生存中值为7.3个月(IQR为3.4~15.4个月),卡铂+多西他赛组患者的生存中值为7.5个月(IQR为3.2~16.0个月)。结论患有晚期NSCLC人群中,卡铂+紫杉醇治疗的存活时间略长于卡铂+吉西他滨治疗或卡铂+多西他赛治疗在鳞癌患者中非常显著。
OBJECTIVE: The efficacy of various combinations of platinum-containing drugs in the treatment of advanced non-small cell lung cancer (NSCLC) is similar, and the relative efficiency and comparability of different combinations in squamous and non-squamous cell carcinomas are determined. Methods The first-line chemotherapeutic agents were identified in our hospital database for the treatment of NSCLC patients with stage IIIB or IV disease from 2000 to 2007. To compare the overall survival of patients with carboplatin + paclitaxel, carboplatin + gemcitabine and carboplatin + docetaxel three chemotherapy regimens. Results Of the 1011 patients receiving first-line chemotherapy, 438 received carboplatin and paclitaxel, 281 received carboplatin and gemcitabine, 247 received carboplatin and docetaxel, and 45 received additional treatment Program. The median survival for patients in the carboplatin and paclitaxel groups was 8.0 months [IQR 3.55 to 17.4 months], median survival 7.3 months for carboplatin plus gemcitabine (IQR 3.4 to 15.4 Month), median survival for patients in the carboplatin + docetaxel group was 7.5 months (IQR, 3.2 to 16.0 months). Conclusions Of the patients with advanced NSCLC, survival of carboplatin + paclitaxel is slightly longer than carboplatin + gemcitabine or carboplatin + docetaxel in patients with squamous cell carcinoma.